cas 136725-55-8|| where to buy (3R)-3-fluoropyrrolidine hydrochloride

Nombre del producto:(3R)-3-fluoropyrrolidine hydrochloride

IUPAC Name:(3R)-3-fluoropyrrolidine hydrochloride

Unidad de embalaje	Stock disponible	Precio($)
CM106718-10g	in stock	ƿȯ
CM106718-25g	in stock	ǫȐƛ
CM106718-100g	in stock	ƛƃŪ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 136725-55-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :136725-55-8; Fórmula molecular:C4H9ClFN; Punto de fusión:-; Código de sonrisas:F[C@H]1CNCC1.[H]Cl; Densidad:

: Número de catálogo:CM106718; Peso molecular:125.57; Punto de ebullición:; Nº Mdl:MFCD04038717; Almacenamiento:

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: Plixorafenib; FORE Biotherapeutics’s Plixorafenib (PLX-8394) is a next-generation, orally selective inhibitor and specific dimer breaker of BRAF protein under clinical development. Its favorable efficacy and tolerability are updated in the recently presented phase 1/2a results in BRAF V600 advanced solid tumors. Plixorafenib was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF. It has been granted Fast Track Designation and Orphan Drug Designation from the U.S. FDA.